Brief: Assembly Biosciences Doses First Participant In Phase 1B Portion Of Phase 1A/B Clinical Trial Of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor Abi-1179
30/06/2025 13:12
Assembly Biosciences Inc ASMB.O: ASSEMBLY BIOSCIENCES DOSES FIRST PARTICIPANT IN PHASE 1B PORTION OF PHASE 1A/B CLINICAL TRIAL OF INVESTIGATIONAL LONG-ACTING HERPES SIMPLEX VIRUS HELICASE-PRIMASE INHIBITOR ABI-1179 ASSEMBLY BIOSCIENCES INC - INTERIM DATA FOR ABI-5366 AND ABI-1179 EXPECTED IN FALL 2025 Source text: ID:nGNX7VGMtD Further company coverage: ASMB.O